Detalhe da pesquisa
1.
A Bayesian framework to study tumor subclone-specific expression by combining bulk DNA and single-cell RNA sequencing data.
Genome Res
; 34(1): 94-105, 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38195207
2.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
N Engl J Med
; 389(1): 33-44, 2023 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37407001
3.
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Blood
; 143(16): 1616-1627, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38215395
4.
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Blood
; 142(8): 687-699, 2023 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37390310
5.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024.
J Natl Compr Canc Netw
; 22(3): 175-204, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38626800
6.
Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis.
Am J Hematol
; 99(4): 780-784, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38357757
7.
Disruption of Nurse-like Cell Differentiation as a Therapeutic Strategy for Chronic Lymphocytic Leukemia.
J Immunol
; 209(6): 1212-1223, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35995507
8.
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Blood
; 137(24): 3327-3338, 2021 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33786588
9.
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
Blood
; 138(23): 2372-2382, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34314481
10.
Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
Am J Hematol
; 98(1): 56-65, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36216791
11.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet
; 397(10277): 892-901, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676628
12.
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Blood
; 135(15): 1204-1213, 2020 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31876911
13.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
J Natl Compr Canc Netw
; 20(6): 622-634, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35714675
14.
Management of relapsed/refractory Chronic Lymphocytic Leukemia.
Am J Hematol
; 97 Suppl 2: S11-S18, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36125037
15.
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Lancet
; 395(10232): 1278-1291, 2020 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305093
16.
Time-Limited Initial Therapy for Young, Fit Patients with CLL.
N Engl J Med
; 388(19): 1812-1813, 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37163628
17.
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
N Engl J Med
; 379(26): 2517-2528, 2018 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30501481
18.
Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
Blood
; 134(21): 1796-1801, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31751484
19.
Hypertension and incident cardiovascular events following ibrutinib initiation.
Blood
; 134(22): 1919-1928, 2019 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31582362
20.
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Blood
; 133(19): 2031-2042, 2019 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30842083